Roles of Prolyl Isomerases in RNA-Mediated Gene Expression
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
32-2709: PPIL1 Recombinant Protein Description Product Info Application
9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-2709: PPIL1 Recombinant Protein Alternative Name : Peptidyl-Prolyl Cis-Trans Isomerase-Like 1,PPIL-1,CYPL1,hCyPX,MGC678,PPIase,CGI-124,PPIL1. Description Source : Escherichia Coli. PPIL1 Human Recombinant protein produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 174 amino acids (1-166) and having a molecular mass of 19.3 kDa. PPIL1 is fused to 8 amino acid His Tag at C-terminus and is purified by proprietary chromatographic techniques. PPIL1 belongs to the cyclophilin family of peptidylprolyl isomerases (PPIases). The cyclophilins are a well conserved, ubiquitous family, members of which take an significant part in protein folding, immunosuppression by cyclosporin A, and infection of HIV-1 virions. PPIL1 protein increases the folding of proteins and catalyze the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. PPIL1 is involved in proliferation of cancer cells through modulation of phosphorylation of stathmin. PPIL1 is a novel molecular target for colon- cancer therapy. Product Info Amount : 50 µg Purification : Greater than 95.0% as determined by SDS-PAGE. Content : PPIL1 solution containing 20 mM Tris-HCl buffer (pH 8.0) and 20% glycerol PPIL1 Human Recombinant although stable at 4°C for 1 week, should be stored desiccated below Storage condition : -18°C. Please prevent freeze thaw cycles. Amino Acid : MAAIPPDSWQ PPNVYLETSM GIIVLELYWK HAPKTCKNFA ELARRGYYNG TKFHRIIKDF MIQGGDPTGT GRGGASIYGK QFEDELHPDL KFTGAGILAM ANAGPDTNGS QFFVTLAPTQ WLDGKHTIFG RVCQGIGMVN RVGMVETNSQ DRPVDDVKII KAYPSGLEHH HHHH. Application Note Specific activity is > 300 nmoles/min/mg, and is defined as the amount of enzyme that cleaves 1umole of suc-AAFP-pNA per minute at 25C in Tris-Hcl pH8.0 using chymotrypsin. -
Compression of Large Sets of Sequence Data Reveals Fine Diversification of Functional Profiles in Multigene Families of Proteins
Technical note Compression of Large Sets of Sequence Data Reveals Fine Diversification of Functional Profiles in Multigene Families of Proteins: A Study for Peptidyl-Prolyl cis/trans Isomerases (PPIase) Andrzej Galat Retired from: Service d’Ingénierie Moléculaire des Protéines (SIMOPRO), CEA-Université Paris-Saclay, France; [email protected]; Tel.: +33-0164465072 Received: 21 December 2018; Accepted: 21 January 2019; Published: 11 February 2019 Abstract: In this technical note, we describe analyses of more than 15,000 sequences of FK506- binding proteins (FKBP) and cyclophilins, also known as peptidyl-prolyl cis/trans isomerases (PPIases). We have developed a novel way of displaying relative changes of amino acid (AA)- residues at a given sequence position by using heat-maps. This type of representation allows simultaneous estimation of conservation level in a given sequence position in the entire group of functionally-related paralogues (multigene family of proteins). We have also proposed that at least two FKBPs, namely FKBP36, encoded by the Fkbp6 gene and FKBP51, encoded by the Fkbp5 gene, can form dimers bound via a disulfide bridge in the nucleus. This type of dimer may have some crucial function in the regulation of some nuclear complexes at different stages of the cell cycle. Keywords: FKBP; cyclophilin; PPIase; heat-map; immunophilin 1 Introduction About 30 years ago, an exciting adventure began in finding some correlations between pharmacological activities of macrocyclic hydrophobic drugs, namely the cyclic peptide cyclosporine A (CsA), and two macrolides, namely FK506 and rapamycin, which have profound and clinically useful immunosuppressive effects, especially in organ transplantations and in combating some immune disorders. -
Pin1 Inhibitors: Towards Understanding the Enzymatic
Pin1 Inhibitors: Towards Understanding the Enzymatic Mechanism Guoyan Xu Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University In the partial fulfillment of the requirement for the degree of Doctor of Philosophy In Chemistry Felicia A Etzkorn, Chair David G. I. Kingston Neal Castagnoli Paul R. Carlier Brian E. Hanson May 6, 2010 Blacksburg, Virginia Keywords: Pin1, anti-cancer drug target, transition-state analogues, ketoamides, ketones, reduced amides, PPIase assay, inhibition Pin1 Inhibitors: Towards Understanding the Enzymatic Mechanism Guoyan Xu Abstract An important role of Pin1 is to catalyze the cis-trans isomerization of pSer/Thr- Pro bonds; as such, it plays an important role in many cellular events through the effects of conformational change on the function of its biological substrates, including Cdc25, c- Jun, and p53. The expression of Pin1 correlates with cyclin D1 levels, which contributes to cancer cell transformation. Overexpression of Pin1 promotes tumor growth, while its inhibition causes tumor cell apoptosis. Because Pin1 is overexpressed in many human cancer tissues, including breast, prostate, and lung cancer tissues, it plays an important role in oncogenesis, making its study vital for the development of anti-cancer agents. Many inhibitors have been discovered for Pin1, including 1) several classes of designed inhibitors such as alkene isosteres, non-peptidic, small molecular Pin1 inhibitors, and indanyl ketones, and 2) several natural products such as juglone, pepticinnamin E analogues, PiB and its derivatives obtained from a library screen. These Pin1 inhibitors show promise in the development of novel diagnostic and therapeutic anticancer drugs due to their ability to block cell cycle progression. -
Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments. -
(12) Patent Application Publication (10) Pub. No.: US 2008/0261923 A1 Etzkorn Et Al
US 20080261923A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0261923 A1 Etzkorn et al. (43) Pub. Date: Oct. 23, 2008 54) ALKENE MIMICS Related U.S. Applicationpp Data (76) Inventors: Felicia A. Etzkorn, Blacksburg, VA (60) Provisional application No. 60/598.421, filed on Aug. (US); Xiaodong X. Wang, 4, 2004. Maricopa, AZ (US); Bulling Xu, Publication Classification Blacksburg, VA (US) (51) Int. Cl. Correspondence Address: A63/675 (2006.01) WHITHAM, CURTIS & CHRISTOFFERSON & C07F 9/06 (2006.01) COOK, PC A6IP35/00 (2006.01) 9 Lew e 11491 SUNSET HILLS ROAD, SUITE 340 A6II 3/662 (2006.01) RESTON, VA 20190 (US) (52) U.S. Cl. ............... 514/80; 546/22: 548/414: 546/23; 548/112:558/166; 514/89: 514/114 (22) PCT Filed: Jul. 29, 2005 Ac-Phe-Tyr-phosphoSer-CH=C-Pro-Arg-NHAND Fmoc-bis(pivaloylmethoxy)phosphoSer-CH=C-Pro-2- (86). PCT No.: PCT/USOS/26821 aminoethyl-(3-indole); and their Phospho-(D)-serine stereoi Somers are novel compounds. I refers to a pseudo amide. S371 (c)(1), Such novel compounds advantageously may be used as alk (2), (4) Date: Sep. 26, 2007 ene mimics. US 2008/0261923 A1 Oct. 23, 2008 ALKENE MIMICS 0005. The possibility of Pin1 activity led to interest and work on certain alkene mimics. (Wang, Supra); Wang, X. J., FIELD OF THE INVENTION Xu, B., Mullins, A. B., Neiler, F.K., and Etzkorn, F.A. (2004), Conformationally Locked Isostere of PhosphoSer-cis-Pro 0001. This invention relates to the design and synthesis of Inhibits Pin1 23-Fold Better than PhosphoSer-trans-Pro Isos compounds that are alkene mimics. -
Role of Protein Repair Enzymes in Oxidative Stress Survival And
Shome et al. Annals of Microbiology (2020) 70:55 Annals of Microbiology https://doi.org/10.1186/s13213-020-01597-2 REVIEW ARTICLE Open Access Role of protein repair enzymes in oxidative stress survival and virulence of Salmonella Arijit Shome1* , Ratanti Sarkhel1, Shekhar Apoorva1, Sonu Sukumaran Nair2, Tapan Kumar Singh Chauhan1, Sanjeev Kumar Bhure1 and Manish Mahawar1 Abstract Purpose: Proteins are the principal biomolecules in bacteria that are affected by the oxidants produced by the phagocytic cells. Most of the protein damage is irreparable though few unfolded proteins and covalently modified amino acids can be repaired by chaperones and repair enzymes respectively. This study reviews the three protein repair enzymes, protein L-isoaspartyl O-methyl transferase (PIMT), peptidyl proline cis-trans isomerase (PPIase), and methionine sulfoxide reductase (MSR). Methods: Published articles regarding protein repair enzymes were collected from Google Scholar and PubMed. The information obtained from the research articles was analyzed and categorized into general information about the enzyme, mechanism of action, and role played by the enzymes in bacteria. Special emphasis was given to the importance of these enzymes in Salmonella Typhimurium. Results: Protein repair is the direct and energetically preferred way of replenishing the cellular protein pool without translational synthesis. Under the oxidative stress mounted by the host during the infection, protein repair becomes very crucial for the survival of the bacterial pathogens. Only a few covalent modifications of amino acids are reversible by the protein repair enzymes, and they are highly specific in activity. Deletion mutants of these enzymes in different bacteria revealed their importance in the virulence and oxidative stress survival. -
Table S2.Up Or Down Regulated Genes in Tcof1 Knockdown Neuroblastoma N1E-115 Cells Involved in Differentbiological Process Anal
Table S2.Up or down regulated genes in Tcof1 knockdown neuroblastoma N1E-115 cells involved in differentbiological process analysed by DAVID database Pop Pop Fold Term PValue Genes Bonferroni Benjamini FDR Hits Total Enrichment GO:0044257~cellular protein catabolic 2.77E-10 MKRN1, PPP2R5C, VPRBP, MYLIP, CDC16, ERLEC1, MKRN2, CUL3, 537 13588 1.944851 8.64E-07 8.64E-07 5.02E-07 process ISG15, ATG7, PSENEN, LOC100046898, CDCA3, ANAPC1, ANAPC2, ANAPC5, SOCS3, ENC1, SOCS4, ASB8, DCUN1D1, PSMA6, SIAH1A, TRIM32, RNF138, GM12396, RNF20, USP17L5, FBXO11, RAD23B, NEDD8, UBE2V2, RFFL, CDC GO:0051603~proteolysis involved in 4.52E-10 MKRN1, PPP2R5C, VPRBP, MYLIP, CDC16, ERLEC1, MKRN2, CUL3, 534 13588 1.93519 1.41E-06 7.04E-07 8.18E-07 cellular protein catabolic process ISG15, ATG7, PSENEN, LOC100046898, CDCA3, ANAPC1, ANAPC2, ANAPC5, SOCS3, ENC1, SOCS4, ASB8, DCUN1D1, PSMA6, SIAH1A, TRIM32, RNF138, GM12396, RNF20, USP17L5, FBXO11, RAD23B, NEDD8, UBE2V2, RFFL, CDC GO:0044265~cellular macromolecule 6.09E-10 MKRN1, PPP2R5C, VPRBP, MYLIP, CDC16, ERLEC1, MKRN2, CUL3, 609 13588 1.859332 1.90E-06 6.32E-07 1.10E-06 catabolic process ISG15, RBM8A, ATG7, LOC100046898, PSENEN, CDCA3, ANAPC1, ANAPC2, ANAPC5, SOCS3, ENC1, SOCS4, ASB8, DCUN1D1, PSMA6, SIAH1A, TRIM32, RNF138, GM12396, RNF20, XRN2, USP17L5, FBXO11, RAD23B, UBE2V2, NED GO:0030163~protein catabolic process 1.81E-09 MKRN1, PPP2R5C, VPRBP, MYLIP, CDC16, ERLEC1, MKRN2, CUL3, 556 13588 1.87839 5.64E-06 1.41E-06 3.27E-06 ISG15, ATG7, PSENEN, LOC100046898, CDCA3, ANAPC1, ANAPC2, ANAPC5, SOCS3, ENC1, SOCS4, -
Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes
2137 Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes Joan P. Breyer,1 Kate M. McReynolds,1 Brian L. Yaspan,2 Kevin M. Bradley,1 William D. Dupont,3 and Jeffrey R. Smith1,2,4 Departments of 1Medicine, 2Cancer Biology, and 3Biostatistics, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine; and 4Medical Research Service, VA Tennessee Valley Healthcare System, Nashville, Tennessee Abstract The genetic variants underlying the strong heritable at genome-wide association study loci 8q24, 11q13, and À À component ofprostate cancer remain largely unknown. 2p15 (P =2.9Â 10 4 to P =4.7Â 10 5), showing study Genome-wide association studies ofprostate cancer population power. We also find evidence to support have yielded several variants that have significantly reported associations at candidate genes RNASEL, replicated across studies, predominantly in cases EZH2, and NKX3-1 (P = 0.031 to P = 0.0085). We unselected for family history of prostate cancer. further explore a set of candidate genes related to Additional candidate gene variants have also been RNASEL and to its role in retroviral restriction, proposed, many evaluated within familial prostate identifying nominal associations at XPR1 and RBM9. cancer study populations. Such variants hold great The effects at 8q24 seem more pronounced for those potential value for risk stratification, particularly for diagnosed at an early age, whereas at 2p15 and early-onset or aggressive prostate cancer, given the RNASEL the effects were more pronounced at a later comorbidities associated with current therapies. Here, age. However, these trends did not reach statistical we investigate a Caucasian study population of523 significance. -
In This Table Protein Name, Uniprot Code, Gene Name P-Value
Supplementary Table S1: In this table protein name, uniprot code, gene name p-value and Fold change (FC) for each comparison are shown, for 299 of the 301 significantly regulated proteins found in both comparisons (p-value<0.01, fold change (FC) >+/-0.37) ALS versus control and FTLD-U versus control. Two uncharacterized proteins have been excluded from this list Protein name Uniprot Gene name p value FC FTLD-U p value FC ALS FTLD-U ALS Cytochrome b-c1 complex P14927 UQCRB 1.534E-03 -1.591E+00 6.005E-04 -1.639E+00 subunit 7 NADH dehydrogenase O95182 NDUFA7 4.127E-04 -9.471E-01 3.467E-05 -1.643E+00 [ubiquinone] 1 alpha subcomplex subunit 7 NADH dehydrogenase O43678 NDUFA2 3.230E-04 -9.145E-01 2.113E-04 -1.450E+00 [ubiquinone] 1 alpha subcomplex subunit 2 NADH dehydrogenase O43920 NDUFS5 1.769E-04 -8.829E-01 3.235E-05 -1.007E+00 [ubiquinone] iron-sulfur protein 5 ARF GTPase-activating A0A0C4DGN6 GIT1 1.306E-03 -8.810E-01 1.115E-03 -7.228E-01 protein GIT1 Methylglutaconyl-CoA Q13825 AUH 6.097E-04 -7.666E-01 5.619E-06 -1.178E+00 hydratase, mitochondrial ADP/ATP translocase 1 P12235 SLC25A4 6.068E-03 -6.095E-01 3.595E-04 -1.011E+00 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 Protein kinase C and casein Q9BY11 PACSIN1 3.837E-03 -5.863E-01 3.680E-06 -1.824E+00 kinase substrate in neurons protein 1 Tubulin polymerization- O94811 TPPP 6.466E-03 -5.755E-01 6.943E-06 -1.169E+00 promoting protein MIC C9JRZ6 CHCHD3 2.912E-02 -6.187E-01 2.195E-03 -9.781E-01 Mitochondrial 2- -
Genequery™ Human Cdna Evaluation Kit, Deluxe (GQH-CED) Catalog #GK991 100 Reactions
GeneQuery™ Human cDNA Evaluation Kit, Deluxe (GQH-CED) Catalog #GK991 100 reactions Product Description ScienCell's GeneQuery™ Human cDNA Evaluation Kit, Deluxe (GQH-CED) assesses cDNA quality. The kit verifies successful reverse transcription of messenger RNA (mRNA) to complementary DNA (cDNA), reveals the presence of genomic DNA (gDNA) contamination in cDNA samples, and detects qPCR inhibitor contamination. Good quality cDNA is a critical component for successful gene expression profiling. The GQH-CED kit is highly recommended for cDNA applications such as GeneQuery™ qPCR arrays. Each primer set included in GQH-CED qPCR kit arrives lyophilized in a 2 mL vial. All primers are designed and tested under the same parameters: (i) an optimal annealing temperature of 65°C (with 2 mM Mg 2+ , and no DMSO); (ii) recognition of all known target gene transcript variants; and (iii) specific amplification of only one amplicon. Each primer set has been validated by qPCR by melt curve analysis and gel electrophoresis. GeneQuery™ Human cDNA Evaluation Kit, Deluxe Components Cat. No. Quantity Component Amplicon size Human LDHA cDNA primer set GK991a 1 vial 130 bp (lyophilized, 100 reactions) Human PPIH cDNA primer set GK991b 1 vial 149 bp (lyophilized, 100 reactions) Human genomic DNA Control (GDC) primer set GK991c 1 vial 81 bp (lyophilized, 100 reactions) Positive PCR Control (PPC) primer set GK991d 1 vial 147 bp (lyophilized, 100 reactions) GK991e 8 mL Nuclease-free H 2O N/A • LDHA cDNA primer set targets housekeeping gene LDHA. The forward and reverse primers are located on different exons, giving variant amplicon sizes for cDNA and gDNA. -
A Portable BRCA1-HAC (Human Artificial Chromosome) Module For
Published online 26 September 2014 Nucleic Acids Research, 2014, Vol. 42, No. 21 e164 doi: 10.1093/nar/gku870 A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function Artem V. Kononenko1, Ruchi Bansal2, Nicholas C.O. Lee1, Brenda R. Grimes2, Hiroshi Masumoto3, William C. Earnshaw4, Vladimir Larionov1 and Natalay Kouprina1,* 1Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892, USA, 2Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA, 3Laboratory of Cell Engineering, Department of Frontier Research, Kazusa DNA, Research Institute, 2-6-7 Kazusa-Kamatari, Kisarazu, Chiba 292-0818, Japan and 4Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3JR, Scotland Downloaded from Received August 04, 2014; Revised September 03, 2014; Accepted September 10, 2014 ABSTRACT INTRODUCTION http://nar.oxfordjournals.org/ BRCA1 is involved in many disparate cellular func- BRCA1 is a well-known tumor suppressor gene, germ line tions, including DNA damage repair, cell-cycle check- mutations in which predispose women to breast and ovarian point activation, gene transcriptional regulation, cancers. Since the identification of the BRCA1 gene, there DNA replication, centrosome function and others. have been numerous studies aimed at characterizing the di- The majority of evidence strongly favors the mainte- verse repertoire of its biological functions. BRCA1 is in- volved in multiple cellular pathways, including DNA dam- nance of genomic integrity as a principal tumor sup- age repair, chromatin remodeling, X-chromosome inactiva- pressor activity of BRCA1. At the same time some tion, centrosome duplication and cell-cycle regulation (1– at Ruth Lilly Medical Library on March 18, 2016 functional aspects of BRCA1 are not fully under- 7). -
Produktinformation
Produktinformation Diagnostik & molekulare Diagnostik Laborgeräte & Service Zellkultur & Verbrauchsmaterial Forschungsprodukte & Biochemikalien Weitere Information auf den folgenden Seiten! See the following pages for more information! Lieferung & Zahlungsart Lieferung: frei Haus Bestellung auf Rechnung SZABO-SCANDIC Lieferung: € 10,- HandelsgmbH & Co KG Erstbestellung Vorauskassa Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 Zuschläge F. +43(0)1 489 3961-7 [email protected] • Mindermengenzuschlag www.szabo-scandic.com • Trockeneiszuschlag • Gefahrgutzuschlag linkedin.com/company/szaboscandic • Expressversand facebook.com/szaboscandic FKBP10 Recombinant Protein (OPCD03243) Data Sheet Product Number OPCD03243 Product Page http://www.avivasysbio.com/fkbp10-recombinant-protein-opcd03243.html Product Name FKBP10 Recombinant Protein (OPCD03243) Size 10 ug Gene Symbol FKBP10 Alias Symbols 65kDa, 65 kDa FK506-binding protein, 65 kDa FKBP, AI325255, FK506-binding protein 10, FKBP-10, Fkbp1-rs, Fkbp6, Fkbp65, FKBP65, FKBP-65 , Fkbprp, Fkbp-rs, Fkbp-rs1, Immunophilin FKBP65, Peptidyl-prolyl cis-trans isomerase FKBP10, PPIase FKBP10, Rotamase Molecular Weight 30 kDa Product Format Lyophilized Tag N-terminal His Tag Conjugation Unconjugated NCBI Gene Id 14230 Host E.coli Purity > 95% Source Prokaryotic Expressed Recombinant Official Gene Full Name FK506 binding protein 10 Description of Target PPIases accelerate the folding of proteins during protein synthesis. Reconstitution and Storage Reconstitute in PBS or others. Store at 2-8C for one month. Aliquot and store at -80C for 12 months. Avoid repeated freeze/thaw cycles. Additional Information Endotoxin Level: < 1.0 EU per 1 ug (determined by the LAL method) Additional Information Residues: Val316 - Asp573 Lead Time Domestic: within 1-2 weeks delivery International: 1-3 weeks Formulation Lyophilized in PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.